NEONATAL INHALED NITRIC OXIDE

新生儿吸入一氧化氮

• 批准号: 6309774
• 负责人: RICHARD A. EHRENKRANZ
• 金额: $ 2.58万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6309774
• 关键词: bacterial pneumonia; clinical research; congenital cardiovascular disorder; hernia; human subject; human therapy evaluation; inhalation drug administration; newborn human (0-6 weeks); nitric oxide; pediatric pharmacology; pulmonary hypertension; respiratory distress syndrome of newborn; respiratory insufficiency /failure; respiratory therapy

Inhaled nitric oxide (INO) will be evaluated as a potential therapy for term and near-term infants with hypoxic respiratory failure including infants with primary persistent pulmonary hypertension of the newborn (PPHN), meconium aspiration, sepsis/pneumonia, respiratory distress syndrome, suspected pulmonary hypoplasia, and congenital diaphragmatic hernia (CDH). (This is a NICHD Neonatal Research Network Trial.)

吸入型一氧化氮(INO)将被评估为治疗足月儿和近月儿缺氧性呼吸衰竭的潜在疗法，包括新生儿原发性持续性肺动脉高压(PPHN)、胎粪吸入、败血症/肺炎、呼吸窘迫综合征、疑似肺发育不良和先天性横隔疝(CDH)。(这是NICHD新生儿研究网络试验。)